Oral Paricalcitol in Stage 3 - 5 Chronic Kidney Disease

Inclusion Criteria: * Patient with stage 3 -5 chronic kidney disease (that is, eGFR \< 60 ml/min per 1.73m2) diagnosed for more than 2 months and not expected to start dialysis within the next 12 months, and * Patient with screening echocardiography showing evidence of left ventricular hypertrophy * Patient has not received vitamin D therapy in the previous 4 weeks * For entry into the Treatment Phase, the subject must have: * screening iPTH \>= 55 pg/ml or 5.8pmol/L (determined by the Nichols second-generation assay or similar assay) * serum calcium \< 10.2 mg/dL (2.55 mmol/L) * serum phosphorus =\< 5.2mg/dL (1.68mmol/L) * Ca\*P product \< 54 mg2/dL2 (4.36mmol2/L2) * If female, subject is either not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy), or is of childbearing potential and practicing birth control measures. * Patients who provide informed consent for the study Exclusion Criteria: * Patient with a history of an allergic reaction or significant sensitivity to vitamin D or vitamin D related compounds. * Patient with history of renal stones * Patient with current malignancy * Patients with clinically significant gastrointestinal disease or liver disease * Patient with acute renal failure in the recent three months * Patient with a history of drug or alcohol abuse within six months prior to the screening phase * Patient is known to be human immunodeficiency virus (HIV) positive. * Patient with evidence of poor compliance with diet and medication. * Patient currently receiving medications that may affect calcium, phosphorus metabolism such as calcitonin, cinacalcet, bisphophonates or vitamin D compounds (other than study drug), or other drugs that may affect calcium or bone metabolism, other than females on stable estrogen and/or progestin therapy. * Patients with active granulomatous disease * Patient with pregnancy * Patients currently receiving glucocorticoid steroid or other immunosuppressive treatment or had been administered glucocorticoid or other immunosuppressive treatment for more than 14 days within recent 6 months. * Patients with contraindication for MRI examination